Table 2.
QTOTBMD-0 | QTOTBMD-12 | QTRABBMD-0 | QTRABBMD-12 | QCORTBMD-0 | QCORTBMD-12 | |
---|---|---|---|---|---|---|
Disease activity | ||||||
DAS28/BASDAI-0 | NS | NS |
R=-0.402 p=0.015 |
NS | NS |
R=-0.465 p=0.005 |
DXA parameters | ||||||
DXL2L4BMD-0 |
R=0.399 p=0.016 |
NS |
R=0.437 p=0.008 |
NS | NS |
R=0.493 p=0.004 |
DXL2L4BMD-12 |
R=0.406 p=0.014 |
NS |
R=0.436 p=0.008 |
NS | NS |
R=0.501 p=0.004 |
DXFEMBMD-0 | NS | NS | NS | NS | NS |
R=0.563 p=0.001 |
DXFEMBMD-12 | NS |
R=0.402 p=0.014 |
NS | NS | NS |
R=0.547 p=0.001 |
Bone biochemical markers | ||||||
CTX-12 | NS | NS |
R=0.400 p=0.011 |
NS | NS | NS |
aBonferroni’s correction was applied in order to exclude the effects of multiple comparisons. Therefore in this case p<0.017 is considered statistically significant
Abbreviations: BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMD bone mineral density, CATHK cathepsin K, CTX C-terminal telopeptide, DAS28 28-joint disease-acitivity score, DXFEMBMD DXA femoral neck BMD, DXL2L4BMD DXA lumbar 2-4 vertebral BMD, NS non-significant, OC osteocalcin, P1NP procollagen type I N-propeptide, QCORTBMD QCT cortical bone mineral density, QTOTBMD QCT total bone mineral density, QTRABBMD QCT trabecular bone mineral density, RANKL Receptor Activator of Nuclear κB Ligand